Thus, the identification of a prostate cancer biomarker that can be measured in blood, provided at low cost, is independent of PSA, and accurately identifies CS prostate cancers that would benefit from near-term intervention, is a pressing need. This evidence concerns the gene KLK3 and Familial prostate cancer.